CSF Biomarkers for Alzheimer Disease Diagnosis: Recent and Future Perspectives

Sebastiaan Engelborghs

1Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Belgium
2Memory Clinic, Hospital Network Antwerp (ZNA), Antwerp, Belgium

Until recently, Alzheimer’s disease (AD) was diagnosed clinically by excluding other conditions and pathologies, at best resulting in a diagnosis of probable AD [1]. Compared to autopsy-confirmed diagnoses, only 68% of the dementia patients were correctly diagnosed using these clinical diagnostic criteria for AD [2,3]. Moreover, a clinical diagnosis of probable AD was confined to the dementia stage of the disease, following several years of progressive cognitive deterioration and behavioral changes. The neuropathological brain lesions that consist of senile plaques and neurofibrillary tangles, start developing many years before the first symptoms of the disease appear.

Due to recent insights, AD is no longer considered a clinical dementia syndrome but a progressive pathogenic process that can accurately be identified, also in its earliest stages. Therefore, revised diagnostic criteria for AD were published in 2011 [4-7]. These criteria better reflect the full continuum of AD, from the preclinical over the predementia (mild cognitive impairment, MCI) to the full-blown dementia stages. These revised criteria include cerebrospinal fluid (CSF), imaging and genetic markers that provide biological evidence for AD.

As the brain is in direct contact with the CSF and the flow of proteins to and from the CSF is restricted by the blood-CSF barrier, biochemical changes that reflect pathophysiological processes in the brain are reflected in CSF. The pathological hallmarks of AD are senile plaques and neurofibrillary tangles, which are made up of β-amyloid protein (Aβ) and hyperphosphorylated protein tau (P-tau), respectively. Aβ, total tau (T-tau) and P-tau proteins can reliably be measured in CSF by means of single-analyte ELISAs or a multi-analyte test based on xMAP technology [8]. However, variations in biomarker measurements have been reported, both between and within laboratories [9]. Even when using the same assay, considerable variability in concentrations of AD biomarkers has been found between different centers leading to high variability and different cut-off values. The variations in concentration and diagnostic performance of biomarkers across studies could be the result of several pre-analytical and analytical factors [10]. Assay-related factors (within and between plate and lot) arise from manufacturing variations in the source material for components and reagents in the analytical kits and random variability of the production process. All these items need careful standardization. As such variations jeopardize the introduction of CSF biomarkers in clinical routine and clinical trials, a number of national and international standardization and harmonization initiatives have been initiated which already resulted in a harmonized pre-analytical protocol for CSF biomarkers [11].

Besides the need for improved standardization and harmonization, what is the actual position of the CSF biomarkers Aβ, T-tau, and P-tau for diagnosing AD? In which (differential) diagnostic situations can they be applied? The clinical and diagnostic usefulness and validity of these CSF biomarkers is supported by numerous studies in large and well-defined patient cohorts. In comparison to cognitively healthy elderly (including patients with psychiatric disorders like depression), the CSF biomarker profile in AD patients consists of decreased Aβ and increased T-tau and P-tau levels. In order to improve the diagnostic accuracy, a combination of CSF biomarkers has been proposed. Some studies have addressed this by calculating ratios or developing biomarker models, which has led to a considerable improvement in diagnostic accuracy. A model based on Aβ and T-tau levels was developed that could accurately discriminate AD from controls by means of a discrimination line. This model has been validated in autopsy-confirmed dementia patients, resulting in sensitivity and specificity figures of 100% and 91% [3].

Can CSF biomarkers be applied in patients with mixed neurodegenerative and vascular dementias? As age is the most important risk factor for both neurodegenerative brain disorders and cerebrovascular disease (CVD), many dementia patients have CVD on brain magnetic resonance imaging (MRI) as was confirmed in neuropathological studies. The extent to which these lesions contribute to the clinical symptoms is unclear. Vascular brain injury may in itself cause dementia, but can also trigger amyloid deposition. In case of doubt between vascular dementia (VaD) or mixed AD-VaD pathology in dementia patients, the determination of CSF Aβ, T-tau and P-tau levels is of help to confirm or exclude the AD component in the pathophysiology of the dementia syndrome [12].

Can CSF biomarkers be used for diagnosing AD in the predementia stages of the disease? In MCI patients, concentrations of Aβ, T-tau and P-tau in CSF are strongly associated with the future development of dementia, which was demonstrated in a large prospective study and in several multi-centre studies [13,14]. Also, a CSF AD profile is much more common in patients with MCI and subjective cognitive impairment [15]. In MCI patients with typical clinical symptoms for AD (progressive episodic memory loss) and biomarker evidence of AD, the diagnosis should be ‘MCI due to AD’, referring to the predementia stage of AD [4]. Since the pathological features of AD are present in nondemented elderly, indicative of preclinical AD, one can assume that CSF biomarkers levels are also altered before the onset of symptoms. Furthermore, 36% of cognitively healthy elderly showed an AD-like biomarker profile and the T-tau/ Aβ ratio is a promising preclinical biomarker that might predict cognitive decline in cognitively normal elderly [16,17]. However, studies with longer follow-up periods...
are necessary to accurately describe the predictive value of CSF biomarkers, especially in healthy elderly.

How well do these CSF biomarkers perform for an AD versus non-AD dementia differential diagnosis? In comparison to non-AD dementias, differences in CSF $A_\beta_{42}$, T-tau and P-tau$_{181}$, biomarker concentrations are much less pronounced as compared to cognitively healthy elderly. In general, both $A_\beta_{42}$ and T-tau in patients with non-AD dementias are intermediate between the concentrations that are found in controls and patients with AD, indicative of a large overlap in concentrations found in AD and non-AD patients [18]. This is especially the case in patients with dementia with Lewy bodies (DLB), due to concomitant AD pathology [19]. Nevertheless, diagnostic models based on $A_\beta_{42}$ and P-tau$_{181}$ are able to discriminate AD from a heterogeneous group of non-AD patients with an overall accuracy of more than 80% [3]. Biomarker-based diagnoses were found to be equally accurate as clinical diagnoses that were based on a complete clinical diagnostic work-up [3]. However, the added value of CSF biomarkers could lie within those cases in which the clinical diagnostic work-up is not able to discriminate between AD or non-AD dementias. In the majority of clinically ambiguous cases, a correct diagnosis would have been established by means of the AD versus non-AD biomarker model [20].

Given the limited discriminatory power of the CSF biomarkers $A_\beta_{42}$, T-tau and P-tau$_{181}$, for the differential diagnosis of dementia, new biomarkers are needed. One could think of other CSF biomarkers, like those that are reflective of the pathology of non-AD dementias. Combinations of CSF biomarkers with advanced MRI techniques or positron emission tomography (PET) with specific ligands might also help to improve the differential dementia diagnosis.

Besides improving the accuracy of AD diagnosis in clinical practice, the AD biomarkers will allow for an enrichment of AD cases in clinical trials to evaluate disease-modifying treatments. Once disease-modifying drugs will be available, biomarkers will be of help to establish a correct and early AD diagnosis, even in the preclinical stages of the disease. A correct diagnosis of AD is of importance as the potential disease-modifying treatments that are under study, will probably only be effective in AD and might have significant side effects. In case a disease-modifying treatment can be started in the preclinical phase of the disease, symptoms can subsequently be delayed or even prevented.

References